SCHEMBL9608472

SCHEMBL9608472

CCCCOC(=O)c1ccc(-c2nc(-c3ccccc3O)nc(-c3ccc(C)cc3O)n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 1/20 0.48
HPGD P15428 1/20 0.48
ALOX15 P16050 1/20 0.48
KMT2A Q03164 1/20 0.48
HSD17B10 Q99714 1/20 0.48
ESR1 P03372 5/20 0.48
LMNA P02545 4/20 0.48
CYP1A2 P05177 2/20 0.48
TSHR P16473 2/20 0.48
CYP2C19 P33261 2/20 0.48
CYP2D6 P10635 1/20 0.48
MAPK1 P28482 1/20 0.48
NR1H2 P55055 1/20 0.48
RNASEL Q05823 1/20 0.48
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
PDE4D Q08499 1/20 0.47
CNR2 P34972 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9608474 0.96 MAPT (0.49) MAPTSMN1; SMN2MEN1HPGDALOX15
SCHEMBL12755000 0.95 CNR2 (0.52) MAPTSMN1; SMN2MEN1HPGDALOX15
SCHEMBL9608406 0.92 ESR1 (0.56) MAPTSMN1; SMN2MEN1HPGDALOX15
SCHEMBL12755002 0.91 CNR2 (0.56) MAPTSMN1; SMN2ESR1LMNACYP1A2
SCHEMBL9608473 0.90 MEN1 (0.58) MAPTSMN1; SMN2MEN1HPGDALOX15
SCHEMBL9609331 0.88 MAPT (0.50) MAPTSMN1; SMN2MEN1HPGDALOX15
SCHEMBL9608402 0.88 ALDH1A1 (0.56) MAPTSMN1; SMN2ESR1LMNACYP1A2
SCHEMBL9609332 0.86 MAPT (0.48) MAPTSMN1; SMN2MEN1HPGDALOX15
SCHEMBL9608477 0.85 PRSS1 (0.44) MAPTSMN1; SMN2MEN1HPGDALOX15
SCHEMBL9608480 0.85 PRSS1 (0.44) MAPTSMN1; SMN2MEN1HPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957140-B2 Triazine derivative, ultraviolet absorber, and resin composition FUJIFILM CORPORATION (JP) 2015-02-17 US disclosed
US-8748520-B2 Polycarbonate resin composition containing triazine compound and molded article using the same FUJIFILM CORPORATION (JP) 2014-06-10 US disclosed
US-8623990-B2 Polyester resin composition FUJIFILM CORPORATION (JP) 2014-01-07 US disclosed
US-20120301696-A1 POLYESTER RESIN COMPOSITION FUJIFILM CORPORATION (JP) 2012-11-29 US disclosed
US-20120136098-A1 NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION FUJIFILM CORPORATION (JP) 2012-05-31 US disclosed
US-20110077331-A1 POLYCARBONATE RESIN COMPOSITION CONTAINING TRIAZINE COMPOUND AND MOLDED ARTICLE USING THE SAME FUJIFILM CORPORATION (JP) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136098-A1 NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION C1R, RPSA, H1-2 MAPT 1774/4885SMN1; SMN2 3721/4885MEN1 2282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.